Company Overview - Bicara Therapeutics focuses on bifunctional antibodies that target tumors, with its lead program being an EGFR TGF-beta agent designed to deliver TGF-beta to the tumor microenvironment [2][3] - The company was founded in 2020 and licensed intellectual property from Biocon, continuing development over the past four to five years [3] Clinical Development - Bicara Therapeutics has initiated a registrational trial for its lead program in the recurrent metastatic head and neck cancer setting, which began early last year [3] - The company expects to have top-line data from this trial by mid-2027 [3]